You just read:

Stemline Therapeutics' Lead Clinical Candidate, SL-401, Induces Another Complete Response in a Patient with a Drug-Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

News provided by

Stemline Therapeutics, Inc.

Jan 07, 2013, 08:30 EST